A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs

Imaging correlates of the Blood Brain Barrier disruption in HIV associated neurocognitive disorder and therapeutic implications

(2019) Joga Chaganti et al.   AIDS

Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations

(2019) Pedro Ayuso et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cerebral Vascular Toxicity of Antiretroviral Therapy

(2019) Luc Bertrand et al.   Journal of Neuroimmune Pharmacology

The Neurocognitive Assessment in the Metabolic and Aging Cohort ( NAMACO ) study: baseline participant profile

(2019) M Métral et al.   HIV MEDICINE

The Blood Brain Barrier: A Review of its Anatomy and Physiology in Health and Disease

(2018) Yousra Sharif et al.   CLINICAL ANATOMY

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial

(2018) Alejandro Arenas-Pinto et al.   CLINICAL INFECTIOUS DISEASES

Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders

(2018) M Trunfio et al.   HIV MEDICINE

Risk of Cardiovascular Disease Associated With Exposure To Abacavir Among Individuals With HIV: A Systematic Review And Meta-analyses Of Results From Seventeen Epidemiologic Studies

(2018) Kunchok Dorjee et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro effect of antiretroviral drugs on cultured primary astrocytes: analysis of neurotoxicity and matrix metalloproteinase inhibition

(2018) Tiziana Latronico et al.   JOURNAL OF NEUROCHEMISTRY

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

(2018) Lene Ryom et al.   Lancet HIV

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

(2018) A Borghetti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Unmasking efavirenz neurotoxicity: Time matters to the underlying mechanisms

(2017) Nádia M. Grilo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Psychiatric Symptoms in Patients Receiving Dolutegravir

(2017) Anna Fettiplace et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants

(2017) Katie R Mollan et al.   JOURNAL OF INFECTIOUS DISEASES

CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients

(2017) Tobias Skillbäck et al.   NEUROBIOLOGY OF AGING

Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet

(2017) P.E. Bunney et al.   PHYSIOLOGY & BEHAVIOR

HIV infection as vascular risk: A systematic review of the literature and meta-analysis

(2017) Jose Gutierrez et al.   PLoS One

Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy

(2016) Judith Schouten et al.   AIDS

HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance

(2016) Pornpun Vivithanaporn et al.   AIDS

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

(2016) Mark G.J. de Boer et al.   AIDS

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis

(2016) A. Calcagno et al.   Journal of Neuroimmune Pharmacology

A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication

(2016) Matteo Vassallo et al.   JOURNAL OF NEUROVIROLOGY

Antiretroviral Treatment with Efavirenz Disrupts the Blood-Brain Barrier Integrity and Increases Stroke Severity

(2016) Luc Bertrand et al.   Scientific Reports

Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?

(2015) Jonathan Underwood et al.   AIDS

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

(2015) François Raffi et al.   AIDS

Confocal Imaging–Guided Laser Ablation of Basal Cell Carcinomas: An Ex Vivo Study

(2015) Heidy Sierra et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients

(2015) A. Calcagno et al.   JOURNAL OF NEUROVIROLOGY

Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection

(2015) Josué Pérez-Santiago et al.   JOURNAL OF NEUROVIROLOGY

HIV protease inhibitor exposure predicts cerebral small vessel disease

(2014) Virawudh Soontornniyomkij et al.   AIDS

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

(2014) Katie R. Mollan et al.   ANNALS OF INTERNAL MEDICINE

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

(2014) Alan Winston et al.   CLINICAL INFECTIOUS DISEASES

Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system

(2014) Cagla Akay et al.   JOURNAL OF NEUROVIROLOGY

Controversies in HIV-associated neurocognitive disorders

(2014) Sam Nightingale et al.   LANCET NEUROLOGY

Neuronal toxicity of efavirenz: a systematic review

(2013) Eric H Decloedt et al.   Expert Opinion On Drug Safety

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals

(2012) Andrew Scourfield et al.   AIDS

Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose

(2012) Daniel H. Johnson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Antiretroviral neurotoxicity

(2012) Kevin Robertson et al.   JOURNAL OF NEUROVIROLOGY

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

(2011) C. Wyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Human Immunodeficiency Virus Infection of Human Astrocytes Disrupts Blood-Brain Barrier Integrity by a Gap Junction-Dependent Mechanism

(2011) E. A. Eugenin et al.   JOURNAL OF NEUROSCIENCE

Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response

(2011) A Bacq et al.   MOLECULAR PSYCHIATRY

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients

(2011) N. Ciccarelli et al.   NEUROLOGY

Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: Implications for HIV-associated neurocognitive disorders

(2011) Brian Giunta et al.   Molecular Brain

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

(2010) K. R. Robertson et al.   NEUROLOGY

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

(2010) R. K. Heaton et al.   NEUROLOGY